Navigation Links
Wyeth Chairman Robert Essner Announces June 27 Retirement
Date:4/24/2008

- Bernard Poussot to Become Chairman of the Board -

MADISON, N.J., April 24 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that its Chairman, Robert Essner, 60, has decided to retire from the Company effective June 27, 2008. Mr. Essner has held the position of Chairman since January 2003 and served as Wyeth's Chief Executive Officer from 2001 to 2007. The Company's Board of Directors has elected Bernard Poussot, Wyeth's President and Chief Executive Officer, to the additional position of Chairman, effective June 27, 2008.

Today's announcement is the culmination of a succession plan that began in April 2006 when Mr. Poussot was promoted to President and Vice Chairman. In January 2007, he was named President and Chief Operating Officer and was elected to the Company's Board of Directors. He became CEO on January 1, 2008.

"We thank Bob for his outstanding contributions in leading our Company," said John P. Mascotte, Chairman of the Wyeth Board's Nominating and Governance Committee. "Bob and Bernard have been a great team for many years, and this type of well-planned succession is in the best interests of the Company, its employees and stockholders."

"Bob successfully led Wyeth's transformation from a holding company to what is now a world leader in pharmaceuticals that has grown in annual revenue from $14 billion in 2001 to more than $22 billion in 2007," said Mr. Poussot. "During his tenure, Wyeth became a leader in biotechnology and thanks to his commitment, we now have one of the most extensive Alzheimer's programs in the health care industry."

"It has been an honor and privilege to lead Wyeth's rise to its current position in the top-tier of the pharmaceutical industry," said Mr. Essner. "Bernard and his management team are now prepared to take the Company to an even higher level of success."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
2. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
3. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
4. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
5. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
6. Wyeth Announces Executive Change in Finance Organization
7. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
8. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , February 17, 2017 ... "Biomarkers Market by Product (Consumables, Service), Type (Safety, ... (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - ... market is projected to reach USD 53.34 Billion ... growing at a CAGR of 13.8% during the ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched ... the agricultural industry. Pilot studies are about to get under way for the framework, ... and 5G innovations. The concept is expected to be transferred eventually to other industries ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
(Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
Breaking Biology Technology:
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
(Date:1/19/2017)... Oregon and PUNE, India , January 19, 2017 ... Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," ... growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... owing to high-level security for both public and private sectors. ... ...
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
Breaking Biology News(10 mins):